Genetic Factors in Antidepressant Side Effects Unveiled by Biobank Data
A groundbreaking study using biobank data reveals how genetic variations influence the severity of side effects from antidepressants, paving the way for personalized mental health treatments.
Recent research conducted by scientists at the University of Tartu's Institute of Genomics has shed light on why some individuals experience more pronounced side effects when using antidepressants. By analyzing data from over 13,000 gene donors stored in the Estonian Biobank, researchers examined 25 common side effects across 16 popular antidepressants, including symptoms like nausea, weight fluctuations, sleep disturbances, headaches, and heart palpitations.
The study focused significantly on the CYP2C19 gene, which plays a crucial role in how the body metabolizes certain medications. Variations in this gene, especially the presence of a deletion mutation found in over 3% of Estonians—a genetic trait not previously documented in other populations—were linked to an increased likelihood of side effects. Slow metabolizers, who process drugs more slowly due to their genetic makeup, were nearly 50% more likely to experience adverse effects compared to those with typical metabolic rates, whereas ultra-rapid metabolizers exhibited a lower risk.
These findings emphasize the importance of personalized medicine, suggesting that genetic testing could guide dosage adjustments or alternative therapies to minimize side effects. For example, patients can check their CYP2C19 activity through the Minu Geenivaramu portal. Incorporating genetic variants like the CYP2C19 deletion into pharmacogenetic testing can enhance treatment safety, especially in Estonia.
Furthermore, the research linked genetic predispositions for psychiatric conditions such as schizophrenia and depression, as well as higher BMI, with increased side effect profiles, including weight gain and headaches. Using data mining and natural language processing on clinical records and questionnaires, scientists demonstrated the significant influence of genetics on individual responses to antidepressants.
Overall, this innovative study highlights the potential of using genetic information to tailor antidepressant therapy, leading to more effective and safer mental health treatments while reducing the risk of therapy discontinuation due to adverse effects. The results underscore the importance of integrating pharmacogenetics into clinical practice to optimize patient outcomes.
Source: https://medicalxpress.com/news/2025-07-biobank-individuals-side-effects-antidepressants.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Three Years of 988 Lifeline: Insights into Regional and Personal Usage Variations
Research three years after its launch reveals regional and demographic differences in the usage of the 988 mental health crisis lifeline, highlighting areas for improved outreach and engagement across the U.S.
How Resilience and Perceived Benefits Influence Mental Health in Dementia Caregivers
Research shows that resilience and perceived caregiving benefits significantly improve mental health outcomes for dementia caregivers, highlighting key intervention avenues.
New Call for Integrated Mental Health Care for Individuals with Epilepsy
A new push for integrated mental health services aims to improve care and quality of life for people living with epilepsy, emphasizing the importance of addressing psychological well-being alongside seizures.
